A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings

Comprehensive Analysis of HLA-DR- and HLA-DP4-Restricted CD4+ T Cell Response Specific for the Tumor-Shared Antigen Survivin in Healthy Donors and Cancer Patients

(2014) X.-F. Wang et al.   JOURNAL OF IMMUNOLOGY

Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer

(2010) Rodryg Ramlau et al.   Journal of Thoracic Oncology

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

(2009) Celestia S. Higano et al.   CANCER

The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies

(2009) J. Ozao-Choy et al.   CANCER RESEARCH

Sunitinib Inhibition of Stat3 Induces Renal Cell Carcinoma Tumor Cell Apoptosis and Reduces Immunosuppressive Cells

(2009) H. Xin et al.   CANCER RESEARCH

Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients

(2009) J. S. Ko et al.   CLINICAL CANCER RESEARCH

Vaccine Therapy in Patients with Renal Cell Carcinoma

(2009) Hein Van Poppel et al.   EUROPEAN UROLOGY

Control of Regulatory T Cell Lineage Commitment and Maintenance

(2009) Steven Z. Josefowicz et al.   IMMUNITY

Analysis and Characterization of Antitumor T-cell Response After Administration of Dendritic Cells Loaded With Allogeneic Tumor Lysate to Metastatic Melanoma Patients

(2009) Nadege Bercovici et al.   JOURNAL OF IMMUNOTHERAPY

Harnessing innate and adaptive immunity for adoptive cell therapy of renal cell carcinoma

(2009) Christiane Geiger et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma

(2009) Howard L Kaufman et al.   Journal of Translational Medicine

The E75 HER2/neu peptide vaccine

(2008) Elizabeth A. Mittendorf et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Vaccination of Renal Cell Cancer Patients with Modified Vaccinia Ankara Delivering Tumor Antigen 5T4 (TroVax) Administered with Interleukin 2: A Phase II Trial

(2008) R. J. Amato et al.   CLINICAL CANCER RESEARCH

Safety and Immunologic Response of a Viral Vaccine to Prostate-Specific Antigen in Combination with Radiation Therapy when Metronomic-Dose Interleukin 2 Is Used as an Adjuvant

(2008) R. J. Lechleider et al.   CLINICAL CANCER RESEARCH

Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients

(2008) J. H. Finke et al.   CLINICAL CANCER RESEARCH

Three Phase II Cytokine Working Group Trials of gp100 (210M) Peptide Plus High-Dose Interleukin-2 in Patients With HLA-A2–Positive Advanced Melanoma

(2008) Jeffrey A. Sosman et al.   JOURNAL OF CLINICAL ONCOLOGY